{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:40:09Z","timestamp":1788939609406,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40262-022-01124-3","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T02:03:42Z","timestamp":1651716222000},"page":"1013-1025","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Dose\u2013Exposure\u2013Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3369-6107","authenticated-orcid":false,"given":"Sebastiaan Camiel","family":"Goulooze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1302-678X","authenticated-orcid":false,"given":"Martijn","family":"van Noort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelleke","family":"Snelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-9535","authenticated-orcid":false,"given":"Meike","family":"Brinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0683-2874","authenticated-orcid":false,"given":"Joerg","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-3423","authenticated-orcid":false,"given":"Thomas","family":"Eissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"issue":"24","key":"1124_CR1","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"1124_CR2","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"23","key":"1124_CR3","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"1","key":"1124_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.ajkd.2019.08.007","volume":"75","author":"A Thompson","year":"2020","unstructured":"Thompson A, Smith K, Lawrence J. Change in estimated GFR and albuminuria as end points in clinical trials: a viewpoint from the FDA. Am J Kidney Dis. 2020;75(1):4\u20135.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1124_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1053\/j.ajkd.2019.07.019","volume":"75","author":"F Holtkamp","year":"2020","unstructured":"Holtkamp F, Gudmundsdottir H, Maciulaitis R, Benda N, Thomson A, Vetter T. Change in albuminuria and estimated GFR as end points for clinical trials in early stages of CKD: a perspective from European regulators. Am J Kidney Dis. 2020;75(1):6\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1124_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75(1):84\u2013104.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1124_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000503713","volume":"50","author":"GL Bakris","year":"2019","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):333\u201344.","journal-title":"Am J Nephrol"},{"key":"1124_CR8","doi-asserted-by":"crossref","unstructured":"Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2020.","DOI":"10.1161\/CIRCULATIONAHA.121.055066"},{"issue":"3","key":"1124_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40262-021-01083-1","volume":"61","author":"B Goulooze","year":"2022","unstructured":"Goulooze B, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, Garmann D, Lippert J, Eissing T. Finerenone dose-exposure-serum potassium response analysis of FIDELIO-DKD phase 3: the role of dosing, titration, and inclusion criteria. Clin Pharmacokinet. 2022. https:\/\/doi.org\/10.1007\/s40262-021-01083-1.","journal-title":"Clin Pharmacokinet."},{"issue":"3","key":"1124_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40262-021-01082-2","volume":"61","author":"P van den Berg","year":"2022","unstructured":"van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, Joseph A, Garmann D, Lippert J, Eissing T. Finerenone dose-exposure-primary efficacy response in FIDELIO-DKD phase 3\u2014population pharmacokinetic and time-to-event analysis. Clin Pharmacokinet. 2022. https:\/\/doi.org\/10.1007\/s40262-021-01082-2.","journal-title":"Clin Pharmacokinet."},{"issue":"22","key":"1124_CR11","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1002\/sim.8282","volume":"38","author":"E Vonesh","year":"2019","unstructured":"Vonesh E, Tighiouart H, Ying J, Heerspink HL, Lewis J, Staplin N, Inker L, Greene T. Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. Stat Med. 2019;38(22):4218\u201339.","journal-title":"Stat Med"},{"issue":"6","key":"1124_CR12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821\u201335.","journal-title":"Am J Kidney Dis"},{"key":"1124_CR13","unstructured":"Karlsson MO, Holford N. A tutorial on visual predictive checks. 2008;abstract 1434: p. 17. www.page-meeting.org\/?abstract=1434. Accessed 8 Apr 2022."},{"issue":"3","key":"1124_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-019-00820-x","volume":"59","author":"N Snelder","year":"2020","unstructured":"Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, et al. Population pharmacokinetic and exposure-response analysis of finerenone: insights based on phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease. Clin Pharmacokinet. 2020;59(3):359\u201370.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1124_CR15","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2019010007","volume":"30","author":"LA Inker","year":"2019","unstructured":"Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30(9):1735\u201345.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1124_CR16","first-page":"284","volume":"24","author":"M Weldegiorgis","year":"2015","unstructured":"Weldegiorgis M, de Zeeuw D, Heerspink HJ. Renal end points in clinical trials of kidney disease. Curr Opin Nephrol Hypertens. 2015;24(3):284\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"11","key":"1124_CR17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJM198209093071104","volume":"307","author":"BM Brenner","year":"1982","unstructured":"Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307(11):652\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"1124_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80(3):282\u20137.","journal-title":"Kidney Int"},{"issue":"3","key":"1124_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2011.132","volume":"80","author":"MR Weir","year":"2011","unstructured":"Weir MR. Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success? Kidney Int. 2011;80(3):235\u20137.","journal-title":"Kidney Int"},{"issue":"6","key":"1124_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/MNH.0000000000000541","volume":"28","author":"SW Waijer","year":"2019","unstructured":"Waijer SW, Gansevoort RT, Heerspink HJL. Change in albuminuria as a surrogate endpoint. Curr Opin Nephrol Hypertens. 2019;28(6):519\u201326.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"1124_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7(2):128\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1124_CR22","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309\u201320.","journal-title":"Kidney Int"},{"issue":"2","key":"1124_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/dom.12600","volume":"18","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Ninomiya T, Persson F, Brenner BM, Brunel P, Chaturvedi N, et al. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. Diabetes Obesity Metab. 2016;18(2):169\u201377.","journal-title":"Diabetes Obesity Metab."},{"issue":"12","key":"1124_CR24","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1681\/ASN.2020050723","volume":"31","author":"M Oshima","year":"2020","unstructured":"Oshima M, Neuen BL, Li J, Perkovic V, Charytan DM, de Zeeuw D, et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial. J Am Soc Nephrol. 2020;31(12):2925\u201336.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1124_CR25","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1124_CR26","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.2337\/dc20-1622","volume":"44","author":"F Persson","year":"2021","unstructured":"Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann JFE, Pratley R, et al. Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: a post hoc analysis of the LEADER Trial. Diabetes Care. 2021;44(4):1020\u20136.","journal-title":"Diabetes Care"},{"issue":"8","key":"1124_CR27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof P, Hartmann E, Freyberger A, Pavkovic M, Mathar I, Sandner P, et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am J Nephrol. 2021;52(8):642\u201352.","journal-title":"Am J Nephrol"},{"key":"1124_CR28","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.34067\/KID.0001172021","volume":"360","author":"AY Meraz-Mu\u00f1oz","year":"2021","unstructured":"Meraz-Mu\u00f1oz AY, Weinstein J, Wald R. eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined. Kidney. 2021;360:1042\u20137.","journal-title":"Kidney"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01124-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01124-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01124-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T02:11:11Z","timestamp":1657937471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01124-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1124"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01124-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"24 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LAP&P conducted the analysis as contract research for Bayer. However, LAP&P (SCG, MvN, NS) and HJLH were not paid to contribute to manuscript preparation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SCG, MvN and NS are employed by LAP&P, a CRO working for Bayer. HJLH is co-chairing the executive committee of the ongoing finerenone FIND-CKD trial and advising Bayer including payments. He also had and has various roles in several SGLT2i trials. MB, JL and TE are Bayer employees and potential shareholders of Bayer AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by international review boards, independent ethics committees, and competent authorities according to national and international regulations. FIDELIO-DKD was conducted in accordance with the ICH Harmonized Tripartite Guideline for Good Clinical Practice.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants provided written informed consent before entering the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All study participants provided written informed consent before entering the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data will be made available in an electronic repository in the future, at a date to be specified by Bayer.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"NONMEM analyses codes are provided as Electronic Supplementary Material.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SCG: wrote the manuscript, designed the research, performed the population PK\/PD analysis and analysed the data; HJLH: wrote the manuscript and designed the research; MvN: performed the population PK\/PD analysis and analysed the data; NS: designed the research, supported the population PK\/PD analysis and analysed the data; MB: designed the research; JL: designed the research and wrote the manuscript; TE: wrote the manuscript and designed and steered analysis and research.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}